When does a failure to warn become a product liability claim?
For many women affected by meningioma after long-term use of Depo-Provera, the key question is not whether their GP or nurse acted wrongly. Instead, they want to know why they weren't warned of the risks. In some cases, the answer may lie with the manufacturer of the medicine rather than the healthcare professional who prescribed it.
What this guide covers:
-
What a failure-to-warn pharmaceutical product liability claim involves.
-
Why Depo-Provera and Sayana Press meningioma claims are being investigated.
-
How patient information leaflets and safety warnings can affect a claim.
-
Whether a claim may be against Pfizer rather than your GP or nurse.
-
How Fletchers Solicitors can help you understand your legal options
Understanding product liability claims
A product liability claim investigates whether a pharmaceutical company provided sufficient information about a medicine’s risks and whether earlier warnings could have prevented avoidable harm.
At Fletchers Solicitors, we are acting for women who developed meningiomas after receiving long-term Depo-Provera or Sayana Press injections and are investigating potential claims against Pfizer, the manufacturer of Depo-Provera.
Key information
- October 2024 Warnings were updated to highlight an increased risk of meningioma
- 130+ women Have joined Fletchers' group action investigating potential claims
- Manufacturer responsibility Did the manufacturer provided adequate warnings about potential risks
What is a failure-to-warn pharmaceutical claim?
Pharmaceutical companies have an ongoing responsibility to monitor the safety of medicines and to provide accurate warnings about known risks.
A medicine does not have to be manufactured incorrectly to give rise to a legal claim. A product may also be considered defective if the warnings, instructions or safety information supplied with it are inadequate.
For many years, Depo-Provera was prescribed across the UK as a long-acting contraceptive injection. Many women received repeat injections over extended periods believing the treatment carried no significant long-term neurological risk.
The issue now being investigated is whether women and healthcare professionals were provided with sufficient information about the potential association between prolonged exposure to medroxyprogesterone acetate and meningioma.
Why are Depo-Provera claims being investigated?
In October 2024, warnings were updated to state that prolonged use of Depo-Provera and Sayana Press may be associated with an increased risk of meningioma.
Many women who subsequently developed meningiomas say they had never previously been informed of this risk.
Importantly, many healthcare professionals may also have been unaware of the potential risk.
GPs, family planning clinics and sexual health practitioners generally rely on information supplied through regulatory channels, prescribing guidance and manufacturer warnings when discussing the benefits and risks of treatment.
If a significant safety concern has not been clearly communicated, prescribers cannot be expected to warn patients about information they themselves have not received.
That is why investigations into Depo-Provera are focusing on whether the manufacturer provided adequate warnings and whether stronger information should have been given to both healthcare professionals and patients at an earlier stage.
Why the patient information leaflet matters
Why the patient information leaflet matters
When courts assess pharmaceutical product liability claims, they often examine:
- What adverse event information was available.
- When the manufacturer became aware of potential risks.
- What warnings were provided to regulators.
- What information appeared in the Summary of Product Characteristics (SmPC).
- What information appeared in patient information leaflets.
- Whether updated warnings were introduced promptly enough.
For many women affected by meningioma, a key question is simple:
If a warning had appeared earlier, would they have continued receiving Depo-Provera injections for as long as they did?
A Depo-Provera example
A woman receives Depo-Provera injections for more than ten years.
Throughout that period, she attends regular appointments and continues treatment because she believes it remains safe and appropriate.
Years later, she develops a meningioma requiring neurosurgery.
She subsequently learns that warnings concerning meningioma risk were only added to patient information materials in October 2024.
The legal questions may include:
- Could the meningioma have been linked to prolonged Depo-Provera use?
- When did evidence of the risk become available?
- Were warnings provided quickly enough?
- Would the patient have chosen a different contraceptive option if adequate warnings had been provided sooner?
These are the types of issues currently being investigated in product liability claims against pharmaceutical manufacturers.
Is my claim against my doctor or against Pfizer?
Many women contacting us are concerned that pursuing a claim means criticising their GP, nurse or family planning clinician.
That is not necessarily the case.
In many Depo-Provera claims, healthcare professionals prescribed the medication in accordance with the information available to them at the time.
The focus of a product liability claim may instead be whether Pfizer provided sufficient warnings regarding the long-term risk of meningioma and whether patients and prescribers should have received stronger information earlier.
How Fletchers Solicitors can help
Our Medical Product Liability team is investigating claims on behalf of women diagnosed with meningioma following long-term use of Depo-Provera and Sayana Press. More than 130 women have already joined our group action.
Our investigation focuses on:
- The safety information available over time.
- Regulatory communications.
- Product information supplied to prescribers.
- Patient information leaflets.
- Expert medical evidence concerning causation.
- Whether earlier warnings may have prevented injury.
If you have been diagnosed with a meningioma after receiving Depo-Provera or Sayana Press injections, our team can assess whether you may be eligible to pursue a claim.
A national team, here when you need us
With offices across the UK, we’re never too far away, helping people access specialist advice and support wherever they are.
You're in safe hands
-
THE TIMES BEST LAW FIRM
-
CHAMBERS TOP RANKED LAW FIRM
-
LEGAL 500 TOP TIER FIRM
-
ARMED FORCES COVENANT
-
AVMA - LAWYERS’ SERVICE MEMBER
-
HEADWAY ACCREDITED SOLICITORS
-
SIA - TRUSTED LEGAL PARTNER
-
CBIT - TRUSTED LEGAL PARTNER
Start your claim with confidence
Not sure where to start? We’ll listen, guide you, and give clear, honest advice on what to do next.